EA036177B1 - Ингибиторы дезоксицитидинкиназы - Google Patents

Ингибиторы дезоксицитидинкиназы Download PDF

Info

Publication number
EA036177B1
EA036177B1 EA201690376A EA201690376A EA036177B1 EA 036177 B1 EA036177 B1 EA 036177B1 EA 201690376 A EA201690376 A EA 201690376A EA 201690376 A EA201690376 A EA 201690376A EA 036177 B1 EA036177 B1 EA 036177B1
Authority
EA
Eurasian Patent Office
Prior art keywords
unsubstituted
substituted
nhc
alkyl
membered
Prior art date
Application number
EA201690376A
Other languages
English (en)
Russian (ru)
Other versions
EA201690376A1 (ru
Inventor
Каюс Г. Раду
Чжэн Ли
Рэймонд М. Гипсон
Дзуе Ван
Нагихеттиар Сатиамурти
Арнон Лави
Дженнифер М. Мерфи
Девид А. Натансон
Майкл Е. Джунг
Original Assignee
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния, Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс filed Critical Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Publication of EA201690376A1 publication Critical patent/EA201690376A1/ru
Publication of EA036177B1 publication Critical patent/EA036177B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA201690376A 2013-08-13 2014-08-13 Ингибиторы дезоксицитидинкиназы EA036177B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361865468P 2013-08-13 2013-08-13
PCT/US2014/050931 WO2015023776A2 (en) 2013-08-13 2014-08-13 Deoxycytidine kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201690376A1 EA201690376A1 (ru) 2016-07-29
EA036177B1 true EA036177B1 (ru) 2020-10-09

Family

ID=52468801

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690376A EA036177B1 (ru) 2013-08-13 2014-08-13 Ингибиторы дезоксицитидинкиназы

Country Status (11)

Country Link
US (2) US9598404B2 (zh)
EP (1) EP3033340B1 (zh)
JP (1) JP6542216B2 (zh)
KR (1) KR102330566B1 (zh)
CN (1) CN105658648B (zh)
AU (1) AU2014306673B2 (zh)
BR (1) BR112016003019A2 (zh)
CA (1) CA2920738A1 (zh)
EA (1) EA036177B1 (zh)
IL (1) IL244029B (zh)
WO (1) WO2015023776A2 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015023776A2 (en) * 2013-08-13 2015-02-19 The Regents Of The University Of California Deoxycytidine kinase inhibitors
AU2017205336A1 (en) * 2016-01-08 2018-07-26 The Regents Of The University Of California Deoxycytidine kinase binding compounds
CN106421790B (zh) * 2016-11-25 2018-12-25 复旦大学附属金山医院 Cmpk的抑制剂在制备治疗卵巢癌的药物中的应用
CN109134354B (zh) * 2018-09-19 2022-03-25 天津科技大学 2-吡啶甲基硫醚的合成方法及相关药物的合成工艺
US20220133735A1 (en) 2020-11-02 2022-05-05 Trethera Corporation Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146571A1 (en) * 2006-12-14 2008-06-19 Augeri David J O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
WO2012122368A1 (en) * 2011-03-08 2012-09-13 The Regents Of The University Of California Deoxycytidine kinase binding compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014657A1 (en) * 2006-07-12 2008-01-17 Beckton Dickinson And Company Use of Albumin, Bovine, P-Aminophenyl N-Acetyl B-D Glucosaminide as a Control Line for an Immunoassay Device
WO2010151735A2 (en) * 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
US8653089B2 (en) * 2011-02-09 2014-02-18 F. Hoffmann-La Roche Ag Heterocyclic compounds and methods of use
EP2518071A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2518070A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
US20130123281A1 (en) * 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules
WO2015023776A2 (en) * 2013-08-13 2015-02-19 The Regents Of The University Of California Deoxycytidine kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146571A1 (en) * 2006-12-14 2008-06-19 Augeri David J O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
WO2012122368A1 (en) * 2011-03-08 2012-09-13 The Regents Of The University Of California Deoxycytidine kinase binding compounds

Also Published As

Publication number Publication date
WO2015023776A3 (en) 2015-11-12
JP6542216B2 (ja) 2019-07-10
EP3033340A2 (en) 2016-06-22
WO2015023776A2 (en) 2015-02-19
IL244029A0 (en) 2016-04-21
KR102330566B1 (ko) 2021-11-25
US9598404B2 (en) 2017-03-21
KR20160058785A (ko) 2016-05-25
US20170204090A1 (en) 2017-07-20
EA201690376A1 (ru) 2016-07-29
JP2016530266A (ja) 2016-09-29
AU2014306673A1 (en) 2016-03-03
CA2920738A1 (en) 2015-02-19
US20160237076A1 (en) 2016-08-18
US9981961B2 (en) 2018-05-29
AU2014306673B2 (en) 2018-12-06
CN105658648B (zh) 2020-03-17
EP3033340B1 (en) 2019-12-04
CN105658648A (zh) 2016-06-08
IL244029B (en) 2019-10-31
BR112016003019A2 (pt) 2017-09-12
EP3033340A4 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
Smith et al. Fragment-based discovery of MRTX1719, a synthetic lethal inhibitor of the PRMT5• MTA complex for the treatment of MTAP-deleted cancers
US9629843B2 (en) MTOR modulators and uses thereof
Pardanani et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations
Ali et al. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity
CN101370803B (zh) 作为组蛋白脱乙酰酶抑制剂的取代的吲哚基-烷基-氨基衍生物
EA036177B1 (ru) Ингибиторы дезоксицитидинкиназы
US20230381180A1 (en) Small molecule modulators of ksr-bound mek
BRPI0616245A2 (pt) modulador de metabolismo, seus usos, composiÇço farmaceutica compreendendo o mesmo, bem como mÉtodo para produÇço da referida composiÇço
TW202019880A (zh) 作為神經激肽－１受體拮抗劑的化合物及其用途
Wang et al. Discovery of (R)-1-(3-(4-amino-3-(3-chloro-4-(pyridin-2-ylmethoxy) phenyl)-1 H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one (CHMFL-EGFR-202) as a novel irreversible EGFR mutant kinase inhibitor with a distinct binding mode
WO2017011323A1 (en) Small molecule inhibitors of the mcl-1 oncoprotein and uses thereof
Murphy et al. Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography
Xu et al. Structure-enabled discovery of novel macrocyclic inhibitors targeting glutaminase 1 allosteric binding site
Olszewski et al. Inhibition of glucose transport synergizes with chemical or genetic disruption of mitochondrial metabolism and suppresses TCA cycle-deficient tumors
Brough et al. Application of off-rate screening in the identification of novel pan-isoform inhibitors of pyruvate dehydrogenase kinase
EP4125861A2 (en) Protein-protein interaction stabilizers
WO2021263188A1 (en) Live cell engagement assay
ITTO20100956A1 (it) Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi
US20220142995A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
Armijo Development of and Therapeutic Applications for Novel Inhibitors of Deoxycytidine Kinase
WO2018191171A1 (en) P38 gamma inhibitors and method of use thereof
Armijo et al. Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography.
JP2023513016A (ja) Ｎｅｋ２阻害剤としてのアミノピリミジニルアミノベンゾニトリル誘導体
Wei et al. Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations
CA3147111A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM